Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genizon, NDEI partner for schizophrenia study
Genizon’s study identified multiple genes associated with the disease using DNA samples from patients from the Quebec founder population. Michel Maziade, professor of psychiatry at the University of
Genizon’s study identified multiple genes associated with the disease using DNA samples from patients from the Quebec founder population. Michel Maziade, professor of psychiatry at the University of
Siemens says it can now can offer its customers a comprehensive healthcare solutions’ portfolio, which brings together the entire medical imaging, laboratory diagnostics and clinical information technology (IT)
The award is the final phase of an aggregate of $4.3 million of grant support from the National Institute of Neurological Disorders and Stroke (NINDS), a division of
Under the amended protocol, the primary endpoint for the 160-patient, historically controlled, multi-center Phase III study would change from survival at 100 days to complete response as defined
The closure, which is expected to be completed by the end of December, will result in the loss of four R&D jobs and will contribute approximately E1.5 million
The court sustained two other patents, directed to a specific manufacturing process and to food products that include omega-3 fatty acids (DHA). The ruling clears the way for
The patent will serve to enhance protection of the intellectual property underlying the company’s Promet treatment program for cocaine dependence, and follows the granting of cocaine patents in
The double-blind, parallel, 12-week study with seven treatment arms in almost 1400 patients evaluated 1g of Cordaptive (1g extended-release niacin/20mg laropiprant) co-administered with simvastatin 10mg to 40mg in
Clear platelets II, designed to evaluate the effects of the addition of Integrilin to an anti-thrombotic regimen of aspirin, clopidogrel and bivalirudin in elective percutaneous coronary intervention (PCI)
The Phase III Qnexa program will include two pivotal, double-blind, placebo-controlled, multi-center studies in distinct populations that will compare Qnexa to placebo during a 56-week treatment period. The